Companies › Ever Supreme Bio Technology
3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Oncology, Neurology, Cardiovascular, Infectious disease; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| UMSC01 cells Allogeneic umbilical cord mesenchymal stem cells | – | Phase 2 | ST Elevation Myocardial Infarction; COVID-19 Infection; Multiple Sclerosis | Jun 2027 |
| ADCV01 autologous dendritic cell vaccination | – | Phase 2 | GBM | Dec 2027 |
| HLA-G-CAR.BiTE allogeneic γδ T cells HLA-G-targeted CAR (chimeric antigen receptor) BiTE (bispecific T cell engager) allogeneic | HLA-G | Phase 1 | Solid Tumor | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06147986 | UMSC01 cells | Phase 2 | ST Elevation Myocardial Infarction | Cardiovascular | Jun 2027 |
| NCT06150885 | HLA-G-CAR.BiTE allogeneic γδ T cells | Phase 1 | Solid Tumor | Oncology | Jun 2027 |
| NCT04115761 | ADCV01 | Phase 2 | GBM | Oncology | Dec 2027 |
| NCT05501418 | UMSC01 cells | Phase 1 | COVID-19 Infection | Infectious disease | Dec 2027 |
| NCT05532943 | UMSC01 cells | Phase 1 | Multiple Sclerosis | Neurology | Oct 2028 |
Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Neuboron Bio-SciTech Hrain Biotechnology Marzieh Ebrahimi
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.